The Overlooked Global Warming Cost We Can’t Ignore
Climate change not only impacts patients with respiratory allergies, but it also has potential broad and emerging impacts on patients with food allergies and overall public health.
Attacking Food Allergies: How Technology can Ease the Path to New Treatments Without the Pain
Advances in flow cytometry could enable researchers to uncover valuable insights about food allergies without allergen exposure.
The Human Algorithm: What AI Can’t Replace in Pharma Engagement
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
How Food Allergy Care Has Changed in the Last Decade
The promise of these and other food allergy treatments is immense and research and development, in conjunction with clinical care facilities for food allergy patients, will continue to make more treatment options available for more people in the future.
FDA Rejects ARS Pharma’s Nasal Spray Alternative to Injectable Epinephrine
ARS Pharmaceuticals frames its intranasal epinephrine spray as a needle-free alternative to products such as EpiPen. Though this spray won the backing of an FDA advisory committee, the agency is now requiring that ARS Pharma run another study to support a regulatory submission.
Allermi Raises $3.5M in Seed Funding To Grow DTC Allergy Relief Platform
Allermi's $3.5 million seed funding was led by Nelstone Ventures and included participation from FourSight Capital Partners. The company will use the money to expand nationally.
Online allergy startup raises $1.25M in pre-seed round
Based in San Francisco, Allermi aims to create a national market for a customizable approach to allergy relief pioneered by a California doctor.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Imagine a world without disease
The team behind the World Without Disease Accelerator, part of Janssen Research & Development, one of the Janssen Pharmaceutical companies of Johnson & Johnson, is embracing an ambitious paradigm focused on disease prevention, interception and cure.
EverlyWell garners $2M to add more tests, staff for diagnostic testing startup
Julia Cheek, EverlyWell CEO and cofounder, said in an email that the funding will help the company expand its suite of tests, hire key leadership positions, launch new partnerships and enhance product features this year.
Allergy diagnostics market to reach $3.8bn by 2024
Rising rates of allergies worldwide will cause the global market for allergy diagnostics to nearly triple from $1.3 billion in 2015 to $3.8 billion in 2024, says a new report.
7 biotech and medtech companies confronting the rise of food allergies
From immunotherapies to mobile health apps, here's how biotech and medtech companies are responding to the rising number of children with food allergies.
presented by
The Definitive Guide to Medical Billing Outsourcing: 5 Top Companies
In today’s healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you?
Innovation is in progress to replace the bulky EpiPen with something more practical
There must be some better, more efficient solutions for the essential use of the EpiPen, and Windgap Medical is working on it.
Morning Read: Abbott readies $25B bid for St Jude Medical, research suggests potential for allergy-free public parks
Drug developer Abbott Laboratories is poised to make a $25 billion bid for medical device maker St Jude Medical, allergy free parks could be a thing in the future.
The best way to protect your kids from allergies: Let them play in the dirt
Microbiologist Jason Tetro explains that the best way to protect your child against allergies is to let them get dirty.
Watch out, EpiPen: A better auto-injector for severe allergies is in the works
As allergies rise, so does the need for on-the-spot epinephrine treatment. Windgap Medical wants to win a chunk of this fast-growing, $1.3 billion market.
The business case for Sean Parker’s $24M gift to Stanford for allergy research
Tech entrepreneur Sean Parker just pledged $24 million to Stanford University to set up a new institute for allergy research, and it comes at an important time: We might not be too far, he says, from finding a treatment that’s curative. The new center will be called the Sean N. Parker Center for Allergy Research. It joins a […]